KHẢO SÁT TỶ LỆ SỬ DỤNG CÁC THUỐC ỨC CHẾ HỆ RENIN- ANGIOTENSIN- ALDOSTERON Ở NGƯỜI SUY TIM PHÂN SUẤT TỐNG MÁU THẤT TRÁI GIẢM THEO HƯỚNG DẪN NĂM 2020 CỦA BỘ Y TẾ VIỆT NAM

Abstract

Background: RAASi are one of the indications for treatment of heart failure patients with reduced left ventricular ejection fraction (LVEF) recommended by Vietnam Ministry of Health in 2020. Objectives: To determine the rate of patients prescribed and the average dose of Angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRAs) and angiotensin receptor–neprilysin inhibitor (ARNI) drug. Subjects and methods: A cross-sectional descriptive study on 164 heart failure patients with reduced LVEF at the Cardiology Department of Cho Ray Hospital from March to June 2022. Results: 99.4% of patients were treated with at least 1 out of 4 RAASi drugs. 72.6% of patients were used both ACEI/UCTT/ARNI and MRA. The percentage of patients using ACE inhibitors was 56.7%, ARB inhibitors 4.3%, MRA  84.1% and ARNI 26.8%. The rate of patient using medication dose close to target dose was highest with MRA: 53.6% of patients reached 50-<75% of the target dose, 46.5% reached ≥75% of the target dose; and lowest with ARNI: 22.7% of patients reached <25% of target dose, 59.1% reached 25-<50% of target dose, 18.2% reached 50-<75% of target dose, none of them reached ≥75% of target dose. Conclusion: The prescribed proportion of RAA inhibitors was high but almost under target dose.